1. Raychaudhuri SP, Farber EM: The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 15(1):16-17, 2001
2. Augustin M et al: Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol 90(2):147-151, 2010
3. Gelfand JM et al: The prevalence of psoriasis in African Americans: Results from a population-based study. J Am Acad Dermatol 52(1):23-26, 2005
4. Farber EM, Nall ML: The natural history of psoriasis in 5,600 patients. Dermatologica 148(1):1-18, 1974
5. Fry L: Psoriasis. Br J Dermatol 119(4):445-461, 1988
6. Henseler T, Christophers E: Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13(3):450-456, 1985
7. Nestle FO et al: Skin immune sentinels in health and disease. Nat Rev Immunol 9(10):679-691, 2009
8. Steinberg A et al: A genetic and statistical study of psoriasis. Am J Hum Gen 3:267-281, 1951
9. Lomholt G: Psoriasis: Prevalence, spontaneous course, and genetics. In: Published Ph.D Thesis, edited by G Lomholt. Copenhagen, G.E.C. GAD, 1963
10. Elder JT et al: The genetics of psoriasis. Arch Dermatol 130(2):216-224, 1994
11. Andressen C, Henseler T: Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt 33(4):214-217, 1982
12. Farber EM, Nall ML, Watson W: Natural history of psoriasis in 61 twin pairs. Arch Dermatol 109(2):207-211, 1974
13. Brandrup F et al: Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 62(3):229-236, 1982
14. Duffy DL, Spelman LS, Martin NG: Psoriasis in Australian twins. J Am Acad Dermatol 29(3):428-434, 1993
15. Watson W et al: The genetics of psoriasis. Arch Dermatol 105(2):197-207, 1972
16. Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 273(5281):1516-1517, 1996
17. Sagoo GS et al: Genome-wide studies of psoriasis susceptibility loci: A review. J Dermatol Sci 35(3):171-179, 2004
18. Choonhakarn C et al: Haplotype associations of the major histocompatibility complex with psoriasis in Northeastern Thais. Int J Dermatol 41(6):330-334, 2002
19. Schmitt-Egenolf M et al: Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6- B57-DRB1*0701-DQA1*0201-DQB1*0303: A population- and family-based study. J Invest Dermatol 106(4):711-714, 1996
20. Jenisch S et al: Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: Strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am J Hum Genet 63(1):191-199, 1998
21. Gudjonsson JE et al: Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients–An analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 126(4):740-745, 2006
22. Gladman DD et al: HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 60(3):259-261, 1999
23. Espinoza LR et al: Histocompatibility typing in the seronegative spondyloarthropathies: A survey. Semin Arthritis Rheum 11(3):375-381, 1982
24. Ozawa A et al: HLA class I and II alleles and susceptibility to generalized pustular psoriasis: Significant associations with HLA-Cw1 and HLA-DQB1*0303. J Dermatol 25(9):573-581, 1998
25. Stuart PE et al: Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics reveals locus heterogeneity at PSORS1. Tissue Antigens 76(5):387-397, 2010
26. Mallon E et al: HLA-C and guttate psoriasis. Br J Dermatol 143(6):1177-1182, 2000
27. Barber LD et al: The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. J Exp Med 184(2):735-740, 1996
28. Walsh
EC et al: An integrated haplotype map of the human major histocompatibility complex.
Am J Hum Genet 73(3):580-590, 2003
29. Horton R et al: Gene map of the extended human MHC. Nat Rev Genet 5(12):889-899, 2004
30. Nair RP et al: Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78(5):827-851, 2006
31. Allen M et al: Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. Lab Invest 81(7):969-976, 2001
32. Fan X et al: Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. PLoS Genet 4(3):e1000038, 2008
33. Feng BJ et al: Multiple loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 5(8):e1000606, 2009
34. Nair RP et al: Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet 41(2):199-204, 2009
35. Trembath RC et al: Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6(5):813-820, 1997
36. Karason A et al: Genetics of psoriasis in Iceland: Evidence for linkage of subphenotypes to distinct Loci. J Invest Dermatol 124(6):1177-1185, 2005
37. Tomfohrde J et al: Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264(5162):1141-1145, 1994
38. Nair RP et al: Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 6(8):1349-1356, 1997
39. Samuelsson L et al: A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Hum Genet 105(6):523-529, 1999
40. Hwu WL et al: Mapping of psoriasis to 17q terminus. J Med Genet 42(2):152-158, 2005
41. Zheng J, Jin S, Shi R: Confirmation of PSORS psoriasis susceptibility loci in a Chinese population. Arch Dermatol Res 295(1):14-18, 2003
42. Bhalerao J, Bowcock AM: The genetics of psoriasis: A complex disorder of the skin and immune system. Hum Mol Genet 7(10):1537-1545, 1998
43. Capon F et al: Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116(5):728-730, 2001
44. Enlund F et al: Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet 7(7):783-790, 1999
45. Hewett D et al: Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 79(3):305-314, 2002
46. Huffmeier U et al: Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. J Invest Dermatol 125(5):906-912, 2005
47. Karason A et al: A susceptibility gene for psoriatic arthritis maps to chromosome 16q: Evidence for imprinting. Am J Hum Genet 72(1):125-131, 2003
48. Zhang XJ et al: Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. J Invest Dermatol 119(6):1361-1366, 2002
49. Sagoo GS et al: Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 122(6):1401-1405, 2004
50. Bowcock AM, Krueger JG: Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol 5(9):699-711, 2005
51. Hüffmeier U et al: Lack of evidence for genetic association to RUNX1 binding site at PSORS2 in different German psoriasis cohorts. J Invest Dermatol 124(1):107-110, 2005
52. Stuart P et al: Analysis of RUNX1 binding site and RAPTOR polymorphisms in psoriasis: No evidence for association despite adequate power and evidence for linkage. J Med Genet 43(1):12-17, 2006
53. Segre JA: Epidermal barrier formation and recovery in skin disorders. J Clin Invest 116(5):1150-1158, 2006
54. Altshuler D et al: A haplotype map of the human genome. Nature 437(7063):1299-1320, 2005
55. Li Y et al: Genotype imputation. Annu Rev Genomics Hum Genet 10:387-406, 2009
56. Elder JT et al: Molecular dissection of psoriasis: Integrating genetics and biology. J Invest Dermatol 130(5):1213-1226, 2010
57. Zhang XJ et al: Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41(2):205-210, 2009
58. Ellinghaus E et al: Genome-wide association study reveals association of psoriasis with TRAF3IP2. Nat Genet 42(11):991-995, 2010
59. Stuart LD et al: Follow-up study identifies six novel psoriasis susceptibility loci in the Chinese Han populaton. Nat Genet 42(11):1005-1009, 2010
60. Cargill M et al: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80(2):273-290, 2007
61. Strange A et al: A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42(11):985-990, 2010
62. Capon F et al: Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet 17(13):1938-1945, 2008
63. Chang M et al: Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun 9(2):176-181, 2008
64. Stuart PE et al: Identification of novel susceptibility loci for psoriasis and psoriatic arthritis. Nat Genet 42(11):1000-1004, 2010
65. de Cid R et al: Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 41(2):211-215, 2009
66. Hollox EJ et al: Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 40(1):23-25, 2008
67. Braun-Falco O: Dynamics of growth and regression in psoriatic lesions: Alterations in the skin from normal into a psoriatic lesion, and during regression of psoriatic lesions. In: Psoriasis: Proceedings of the International Symposium, Stanford University, 1971, edited by EM Farber, AJ Cox. Stanford, CA, Stanford University Press, 1971, pp. 215-237
68. Wilkinson DI: Lipid metabolism in psoriasis. In: Psoriasis: Proceedings of the Internatioinal Symposium, Stanford University, 1971, edited by EM Farber, AJ Cox. Stanford, CA, Stanford University Press, 1971, pp. 277-285
69. Gudjonsson JE et al: Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 129(12):2795-2804, 2009
70. Christophers E, Parzefall R, Braun-Falco O: Initial events in psoriasis: Quantitative assessment. Br J Dermatol 89(4):327-334, 1973
71. Ragaz A, Ackerman AB: Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1(3):199-214, 1979
72. Brody I: Alterations of clinically normal skin in early eruptive guttate psoriasis. J Cutan Pathol 5:219-233, 1978
73. Brody I: Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris. J Invest Dermatol 82(5):460-464, 1984
74. Schubert C, Christophers E: Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 277(5):352-358, 1985
75. Baker BS et al: Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110(5):555-564, 1984
76. Bieber T, Braun-Falco O: Distribution of CD1a-positive cells in psoriatic skin during the evolution of the lesions. Acta Derm Venereol 69(2):175-178, 1989
77. Wright NA, Camplejohn RS, eds.: Psoriasis: Cell Proliferation. Edinburgh, London, Melbourne, and New York, Churchill Livingstone, 1983
78. Cox AJ, Watson W: Histological variations in lesions of psoriasis. Arch Dermatol 106(4):503-506, 1972
79. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 361(5):496-509, 2009
80. Gaspari AA: Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 54(3 Suppl. 2):S67-S80, 2006
81. Baker BS et al: Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: The effects of PUVA treatment. Clin Exp Immunol 61(3):526-534, 1985
82. Ellis CN et al:
Cyclosporine improves psoriasis in a double-blind study.
JAMA 256(22):3110-3116, 1986
83. Griffiths C et al: Clearance of psoriasis with low dose cyclosporin. Br Med J 293:731-732, 1986
84. Elder JT et al: Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine-stimulated cultured keratinocytes. J Invest Dermatol 101:761-766, 1993
85. Kanamori H et al: Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: Case report and review of the literature. Am J Hematol 71(1):41-44, 2002
86. Gardembas-Pain M et al: Psoriasis after allogeneic bone marrow transplantation [letter]. Arch Dermatol 126(11):1523, 1990
87. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. J Clin Invest 98(8):1878-1887, 1996
88. Chang JC et al: CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc Natl Acad Sci U S A 91(20):9282-9286, 1994
89. Prinz JC et al: Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol 29(10):3360-3368, 1999
90. Vollmer S, Menssen A, Prinz JC: Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: Evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 117(5):1296-1301, 2001
91. Lin WJ et al: Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol 117(6):1546-1553, 2001
92. Clark RA et al: The vast majority of CLA+ T cells are resident in normal skin. J Immunol 176(7):4431-4439, 2006
93. Austin LM et al: Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J Cutan Pathol 25(2):79-88, 1998
94. Paukkonen K, Naukkarinen A, Horsmanheimo M: The development of manifest psoriatic lesions is linked with the invasion of CD8 + T cells and CD11c +macrophages into the epidermis. Arch Dermatol Res 284(7):375-379, 1992
95. Uyemura K et al: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101(5):701-705, 1993
96. Austin LM et al: The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining
TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients.
J Invest Dermatol 113(5):752-759, 1999
97. Zaba LC et al: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204(13):3183-3194, 2007
98. Eyerich S et al: Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119(12):3573-3585, 2009
99. Iwakura Y, Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest 116(5):1218-1222, 2006
100. Murphy CA et al: Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198(12):1951-1957, 2003
101. Piskin G et al: In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 176(3):1908-1915, 2006
102. Yen HR et al:
Tc17 CD8 T cells: Functional plasticity and subset diversity.
J Immunol 183(11):7161-7168, 2009
103. Annunziato F et al: Phenotypic and functional features of human Th17 cells. J Exp Med. 204(8):1849-1861, 2007
104. Bending D et al: Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 119(3):565-572, 2009
105. Wei G et al: Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30(1):155-167, 2009
106. Zheng Y et al: Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445(7128):648-651, 2007
107. Nograles KE et al: IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing T(H)17 T cells. J Allergy Clin Immunol 123(6):1244-1252, 2009
108. Trifari S et al: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10(8):864-871, 2009
109. Manel N, Unutmaz D, Littman DR: The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9(6):641-649, 2008
110. Wing K, Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11(1):7-13, 2010
111. Beissert S, Schwarz A, Schwarz T: Regulatory T cells. J Invest Dermatol 126(1):15-24, 2006
112. Sugiyama H et al: Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174(1):164-173, 2005
113. Goodman WA et al: IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183(5):3170-3176, 2009
114. Peternel S, Kastelan M: Immunopathogenesis of psoriasis: Focus on natural killer T cells. J Eur Acad Dermatol Venereol 23(10):1123-1127, 2009
115. Ferenczi K et al: CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry. J Autoimmun 14(1):63-78, 2000
116. Bonish B et al: Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 165(7):4076-4085, 2000
117. Nickoloff BJ et al: Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 24(3):212-225, 2000
118. Rajagopalan S, Long EO: Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 201(7):1025-1029, 2005
119. Suzuki Y et al: Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol 122(5):1133-1136, 2004
120. Holm SJ et al: Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J Invest Dermatol 125(4):721-730, 2005
121. Ploski R et al: A role for KIR gene variants other than KIR2DS1 in conferring susceptibility to psoriasis. Hum Immunol 67(7):521-526, 2006
122. Martin MP et al: Cutting edge: Susceptibility to psoriatic arthritis: Influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169(6):2818-2822, 2002
123. Williams F et al: Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 66(7):836-841, 2005
124. Nelson GW et al: Cutting edge: Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 173(7):4273-4276, 2004
125. Reis e Sousa C: Dendritic cells in a mature age. Nat Rev Immunol 6(6):476-483, 2006
126. Wollenberg A et al: Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119(5):1096-1102, 2002
127. Krueger JG, Bowcock A: Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 64(Suppl. 2):ii30-ii36, 2005
128. Zaba LC, Krueger JG, Lowes MA: Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol 129(2):302-308, 2009
129. Kripke ML et al: Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J Immunol 145(9):2833-2838, 1990
130. Wollenberg A et al: Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 106(3):446-453, 1996
131. Abrams JR et al: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192(5):681-694, 2000
132. Fujita H et al: Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A 106(51):21795-21800, 2009
133. Cumberbatch M et al: Impaired Langerhans cell migration in psoriasis. J Exp Med 203(4):953-960, 2006
134. Shaw FL et al: Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. J Invest Dermatol 130(7):1940-1942, 2010
135. Nestle FO et al: Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 151(11):6535-6545, 1993
136. Morganroth GS et al: Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol 96(3):333-340, 1991
137. Lowes MA et al: Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 102(52):19057-19062, 2005
138. Cerio R et al: Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 121(4):421-431, 1989
139. Zaba LC et al: Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 117(9):2517-2525, 2007
140. Zaba LC et al: Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol 125(6):1261-1268, e1269, 2010
141. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and “Type 1” inflammatory gene expression. Trends Immunol 25(6):295-305, 2004
142. Zaba LC et al: Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129(1):79-88, 2009
143. Guttman-Yassky E et al: Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 119(5):1210-1217, 2007
144. Wollenberg A et al: Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. J Invest Dermatol 118(2):327-334, 2002
145. Johnson-Huang LM et al: Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 29(3):247-256, 2009
146. Colonna M, Trinchieri G, Liu YJ: Plasmacytoid dendritic cells in immunity. Nat Immunol 5(12):1219-1226, 2004
147. Nestle FO et al: Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 202(1):135-143, 2005
148. Rajan N, Langtry JA: Generalized exacerbation of psoriasis associated with
imiquimod cream treatment of superficial basal cell carcinomas.
Clin Exp Dermatol 31(1):140-141, 2006
149. Hemmi H et al: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3(2):196-200, 2002
150. Bissonnette R et al: A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 62(3):427-436, 2010
151. Marone G et al: Pharmacological modulation of human mast cells and basophils. Clin Exp Allergy 32(12):1682-1689, 2002
152. Hueber AJ et al: Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184(7):3336-3340, 2010
153. Lin A et al: Mast cells and neutrophils are major sources of IL-17 in psoriasis. J Immunol 187(1):490-500, 2011
154. Fuentes-Duculan J et al: A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 130(10):2412-2422, 2010
155. Gillitzer R et al: MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol 101(2):127-131, 1993
156. Van Den Oord JJ, de Wolf-Peeters C: Epithelium-lining macrophages in psoriasis. Br J Dermatol 130(5):589-594, 1994
157. Boehncke WH et al: A subset of macrophages located along the basement membrane (“lining cells”) is a characteristic histopathological feature of psoriasis. Am J Dermatopathol 17(2):139-144, 1995
158. Pinkus H, Nehregan AH: The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 46:109-116, 1966
159. Clark RA, Kupper TS: Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 116(8):2084-2087, 2006
160. Wang H et al: Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116(8):2105-2114, 2006
161. Stratis A et al: Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 116(8):2094-2104, 2006
162. Grone A: Keratinocytes and cytokines. Vet Immunol Immunopathol 88(1-2):1-12, 2002
163. Duell EA, Ellis CN, Voorhees JJ: Determination of 5,12, and 15-lipoxygenase products in keratomed biopsies of normal and psoriatic skin. J Invest Dermatol 91(5):446-450, 1988
164. Braff MH et al: Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol 125(1):9-13, 2005
165. Mansbridge JN, Knapp AM, Strefling AM: Evidence for an alternative pathway of keratinocyte maturation in psoriasis from an antigen found in psoriatic but not normal epidermis. J Invest Dermatol 83(4):296-301, 1984
166. Krueger JG et al: Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 182(6):2057-2068, 1995
167. Detmar M et al: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141-1146, 1994
168. Xia YP et al: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102(1):161-168, 2003
169. Creamer D et al: Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 136(6):859-865, 1997
170. Szabowski A et al: c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 103(5):745-755, 2000
171. Saiag P et al: Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science 230(4726):669-672, 1985
172. Clark RA et al: A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol 126(5):1059-1070, 2006
173. Prinz JC et al: T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 24(3):593-598, 1994
174. Bata-Csorgo Z et al: Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 95(1):317-327, 1995
175. Nickoloff BJ et al: Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. Br J Dermatol 121(2):161-174, 1989
176. Uyemura K et al: CD4+ type 1 and CD8+ type 2 T cell subsets in human leishmaniasis have distinct T cell receptor repertoires. J Immunol 151(12):7095-7104, 1993
177. Ettehadi P et al: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96(1):146-151, 1994
178. Grossman RM et al: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 86(16):6367-6371, 1989
179. Degiulio R et al: Increased levels of leukotriene B4 and interleukin-8 in psoriatic skin. Ann N Y Acad Sci 685:614-617, 1993
180. Ruckert R et al: High-dose proinflammatory cytokines induce apoptosis of hair bulb keratinocytes in vivo [In Process Citation]. Br J Dermatol 143(5):1036-1039, 2000
181. Teunissen MB et al: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111(4):645-649, 1998
182. Ohta Y, Hamada Y, Katsuoka K: Expression of IL-18 in psoriasis. Arch Dermatol Res 293(7):334-342, 2001
183. Sa SM et al: The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178(4):2229-2240, 2007
184. Caruso R et al: Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15(9):1013-1015, 2009
185. Nickoloff BJ et al: The cytokine and chemokine network in psoriasis. Clin Dermatol 25(6):568-573, 2007
186. Li AG et al: Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. Embo J 23(8):1770-1781, 2004
187. Mee JB et al: Interleukin-1: A key inflammatory mediator in psoriasis? Cytokine 33(2):72-78, 2006
188. Gudjonsson JE, Elder JT: Psoriasis: Etiopathogenesis. In: Psoriatic and Reactive Arthritis: A Companion to Rheumatology, 1st edition, edited by C Ricthlin, CT Ricthlin, O Fitzgerald. Philadelphia, Elsevier, 2006, pp. 37-47
189. Harrington LE et al: Interleukin 17-producing CD4 +effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123-1132, 2005
190. Kryczek I et al: Induction of memory IL-17+ T cell trafficking and expansion by IFN-gamma: Mechanism and pathological relevance. J Immunol 181:4733-4741, 2008
191. Conrad C et al: Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 13(7):836-842, 2007
192. Ong PY et al: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347(15):1151-1160, 2002
193. de Jongh GJ et al: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 125(6):1163-1173, 2005
194. Howell MD et al: Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 125(4):738-745, 2005
195. Christophers E, Henseler T: Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res 279(Suppl.):S48-S51, 1987
196. Eckert RL et al: S100 proteins in the epidermis. J Invest Dermatol 123(1):23-33, 2004
197. Clohessy PA, Golden BE: Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence. Scand J Immunol 42(5):551-556, 1995
198. Glaser R et al: Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 6(1):57-64, 2005
199. Loser K et al: The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8(+) T cells. Nat Med 16(6):713-717, 2010
200. Takematsu H, Tagami J: Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch Dermatol 129:74-80, 1993
201. Mrowietz U et al: Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells. Exp Dermatol 10(4):238-245, 2001
202. McInturff JE, Modlin RL, Kim J: The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol 125(1):1-8, 2005
203. Ikai K: Psoriasis and the arachidonic acid cascade. J Dermatol Sci 21(3):135-146, 1999
204. Elder J: Cytokine and genetic regulation of psoriasis. In: Advances in Dermatology, vol. 10, edited by M Dahl. St. Louis, Mosby-Year Book, 1995, pp. 99-134
205. Piepkorn M, Pittelkow MR, Cook PW: Autocrine regulation of keratinocytes: The emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 111(5):715-721, 1998
206. Bhagavathula N et al: Amphiregulin and epidermal hyperplasia: Amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice. Am J Pathol 166(4):1009-1016, 2005
207. Malhotra R et al: Angiogenic properties of normal and psoriatic skin associate with epidermis, not dermis. Lab Invest 61(2):162-165, 1989
208. Joseph T et al: Unilateral remission of psoriasis following traumatic nerve palsy. Br J Dermatol 152(1):185-186, 2005
209. Raychaudhuri SP et al: K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol 122(3):812-819, 2004
210. Hosoi J et al: Regulation of Langerhans cell function by nerves containing
calcitonin gene-related peptide.
Nature 363(6425):159-163, 1993
211. Krane JF et al: The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med 175(4):1081-1090, 1992
212. Finch PW et al: Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol 151(6):1619-1628, 1997
213. Sanderson MP, Dempsey PJ, Dunbar AJ: Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 24(2):121-136, 2006
214. Meyer-Hoffert U, Wingertszahn J, Wiedow O: Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation. J Invest Dermatol 123(2):338-345, 2004
215. Iwakiri K, Ghazizadeh M, Jin E et al: Human airway trypsin-like protease induces PAR-2-mediated IL-8 release in psoriasis vulgaris. J Invest Dermatol 122(4):937-944, 2004
216. Pfundt R et al: Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. J Clin Invest 98(6):1389-1399, 1996
217. Bylaite M et al: Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases. Exp Dermatol 15(2):110-118, 2006
218. Fyrand O: Studies on fibronectin in the skin. II. Indirect immunofluorescence studies in psoriasis vulgaris. Arch Dermatol Res 266(1):33-41, 1979
219. Bata-Csorgo Z et al: Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J Clin Invest 101(7):1509-1518, 1998
220. De Luca M et al: Role of integrins in cell adhesion and polarity in normal keratinocytes and human skin pathologies. J Dermatol 21(11):821-828, 1994
221. Carroll JM, Romero MR, Watt FM: Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 83(6):957-968, 1995
222. Rottman JB et al: Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 81(3):335-347, 2001
223. Gudjonsson JE et al: Evidence for altered Wnt signaling in psoriatic skin. J Invest Dermatol 130(7):1849-1859, 2010
224. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113(12):1664-1675, 2004
225. Raj D, Brash DE, Grossman D: Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol 126(2):243-257, 2006
226. Gudjonsson JE et al: Mouse models of psoriasis. J Invest Dermatol 127(6):1292-1308, 2007
227. Gudjonsson JE et al: Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 149(3):530-534, 2003
228. Akagi Y et al: A role of tonsillar lymphocyte for focal infection. With special reference to lymphocyte adhesion to vessels in dermis. Adv Otorhinolaryngol 47:129-133, 1992
229. Diluvio L et al: Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 176(11):7104-7111, 2006
230. Gudjonsson JE et al: Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 135(1):1-8, 2004
231. Hammar H et al: Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor/cytotoxic T cells in epidermis during the evolution of the lesion. J Invest Dermatol 83(6):416-420, 1984
232. Boyman O et al: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199(5):731-736, 2004
233. Clark RA: Skin-resident T cells: The ups and downs of on site immunity. J Invest Dermatol 130(2):362-370, 2010
234. Martin BA, Chalmers RJ, Telfer NR: How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 132(6):717-718, 1996
235. Valdimarsson H et al: Psoriasis–As an autoimmune disease caused by molecular mimicry. Trends Immunol 30(10):494-501, 2009
236. Braun-Falco O, Schmoeckel C: The dermal inflammatory reaction in initial psoriatic lesions. Arch Dermatol Res 258(1):9-16, 1977
237. Fischetti
VA: Streptococcal M protein.
Sci Am 264(6):58-65, 1991
238. Sigmundsdottir H et al: Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45(6):688-697, 1997
239. Gudmundsdottir AS et al: Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 117(3):580-586, 1999
240. McFadden J, Valdimarsson H, Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol 125(5):443-447, 1991
241. Leigh IM et al: Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 133(4):501-511, 1995
242. Johnston A et al: Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 138(1):83-93, 2004
243. Kurts C et al: Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188(2):409-414, 1998
244. Stoler A et al: Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J Cell Biol 107(2):427-446, 1988
245. Zhou X et al: Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13(1):69-78, 2003
246. Gudjonsson JE, Ding J, Johnston A et al: Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 130(7):1829-1840, 2010
247. Suarez-Farinas M et al: Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One 5(4):e10247, 2010
248. Oestreicher JL et al: Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 1(4):272-287, 2001
249. Bowcock AM et al: Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 10(17):1793-1805, 2001
250. Nomura I et al: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171(6):3262-3269, 2003
251. Haider AS et al: Cellular genomic maps help dissect pathology in human skin disease. J Invest Dermatol 128(3):606-615, 2008
252. Capon F et al: Searching for psoriasis susceptibility genes in Italy: Genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 112(1):32-35, 1999
253. Kursar M et al: Regulatory CD4+CD25+ T cells restrict memory CD8 +T cell responses. J Exp Med 196(12):1585-1592, 2002
254. Ribeiro RM et al: In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A 99(24):15572-15577, 2002
255. Gudjonsson JE et al: Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol 148(2):233-235, 2003
256. Gudjonsson JE et al: HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 118(2):362-365, 2002
257. Besgen P et al: Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: Potential targets of a streptococcal-induced autoimmune response in psoriasis. J Immunol 184(9):5392-5402
258. Leung DY et al: Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 96(5):2106-2112, 1995
259. Vekony MA et al: Selective amplification of T-cell receptor variable region species is demonstrable but not essential in early lesions of psoriasis vulgaris: Analysis by anchored polymerase chain reaction and hypervariable region size spectratyping. J Invest Dermatol 109(1):5-13, 1997
260. Baker BS et al: Peptidoglycan and peptidoglycan-specific Th1 cells in psoriatic skin lesions. J Pathol 209(2):174-181, 2006
261. Nickoloff BJ et al: Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol 150(6):2148-2159, 1993
262. Heath WR et al: Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199:9-26, 2004
263. Bennett SR et al: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684):478-480, 1998
264. den Haan JM, Bevan MJ: Antigen presentation to CD8+ T cells: Cross-priming in infectious diseases. Curr Opin Immunol 13(4):437-441, 2001
265. Serbina NV et al: CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection. J Immunol 167(12):6991-7000, 2001
266. Hamilton SE et al: The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat Immunol 7(5):475-481, 2006
267. Nickoloff BJ, Wrone-Smith T: Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 155(1):145-158, 1999
268. Krueger GG et al: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356(6):580-592, 2007
269. Lee E et al: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199(1):125-130, 2004
270. Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8(4):345-350, 2007
271. Najarian DJ, Gottlieb AB: Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 48(6):805-821, quiz 822-804, 2003
272. Duerr RH et al: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461-1463, 2006
273. Thomas GP, Brown MA: Genetics and genomics of ankylosing spondylitis. Immunol Rev 233(1):162-180, 2010
274. Reveille JD et al: Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42(2):123-127, 2010
275. Liu Y et al: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4(3):e1000041, 2008
276. Huffmeier U et al: Genetic variants of the IL-23R pathway: Association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 129(2):355-358, 2009
277. Mills KH: Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 38(10):2636-2649, 2008
278. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet 370(9583):263-271, 2007
279. Ghoreschi K et al: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 9(1):40-46, 2003
280. Guenova E et al: IL-4 therapy of psoriasis selectively abrogates IL-23 and Th17 immune responses in humans [abstract]. J Invest Dermatol 129(Suppl. 2):S2, 2009
281. Mauro C et al: ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem 281(27):18482-18488, 2006
282. Plenge RM et al: Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39(12):1477-1482, 2007
283. Thomson W et al: Rheumatoid arthritis association at 6q23. Nat Genet 39(12):1431-1433, 2007
284. Graham RR et al: Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40:1059-1061, 2008
285. Musone SL et al: Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40:1062-1064, 2008
286. Gateva V et al: A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41(11):1228-1233, 2009
287. Han JW et al: Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41(11):1234-1237, 2009
288. Idel S, Dansky HM, Breslow JL: A20, a regulator of NFkappaB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc Natl Acad Sci U S A 100(24):14235-14240, 2003
289. Gelfand JM et al: Risk of myocardial infarction in patients with psoriasis. JAMA 296(14):1735-1741, 2006
290. Lu T et al: Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 107(1):46-51, 2010
291. Jin J et al: Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18(21):2573-2580, 2004
292. Hunter CA: Act1-ivating IL-17 inflammation. Nat Immunol 8(3):232-234, 2007
293. Jackson B et al: Late cornified envelope family in differentiating epithelia–response to calcium and ultraviolet irradiation. J Invest Dermatol 124(5):1062-1070, 2005
294. Zhao XP, Elder JT: Positional cloning of skin-specific genes from the human epidermal differentiation complex. Genomics 45:250-258, 1997
295. Gudjonsson JE et al: Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 130(7):1829-1840, 2010
296. Christophers E: Psoriasis–epidemiology and clinical spectrum. Clin Exp Dermatol 26(4):314-320, 2001
297. Fry L: An Atlas of Psoriasis. Carnforth, Parthenon Publishing, 1992
298. Weiss G, Shemer A, Trau H: The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol 16(3):241-248, 2002
299. van de Kerkhof PC: The Woronoff zone surrounding the psoriatic plaque. Br J Dermatol 139(1):167-168, 1998
300. Telfer NR et al: The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 128(1):39-42, 1992
301. Chalmers RR et al: A systematic review of treatments for guttate psoriasis. Br J Dermatol 145(6):891-894, 2001
302. Mitchell JC, Forstner J: Eccrine function in psoriasis inversus. J Canadian Med Assoc 87(21):1093-1095, 1962
303. Johnson C, Shuster S: Eccrine sweating in psoriasis. Br J Dermatol 81(2):119-124, 1969
304. Cornbleet T: Action of synthetic antimalarial drugs on psoriasis. J Invest Dermatol 26(6):435-436, 1956
305. Ivker RA et al: Infantile generalized pustular psoriasis associated with lytic lesions of the bone. Pediatr Dermatol 10(3):277-282, 1993
306. Prose NS et al: Pustular psoriasis with chronic recurrent multifocal osteomyelitis and spontaneous fractures. J Am Acad Dermatol 31(2 Pt 2):376-379, 1994
307. Beretta-Piccoli BC et al: Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. Eur J Pediatr 159(8):594-601, 2000
308. Baker H, Ryan TJ: Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 80(12):771-793, 1968
309. Zelickson BD, Muller SA: Generalized pustular psoriasis: A review of 63 cases. Arch Dermatol 127(9):1339-1345, 1991
310. Kopp T et al: Successful use of
acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type.
Br J Dermatol 151(4):912-916, 2004
311. Newland MR, Weinstein A, Kerdel F: Rapid response to
infliximab in severe pustular psoriasis, von Zumbusch type.
Int J Dermatol 41(7):449-452, 2002
312. Varma R et al:
Infliximab for the treatment of severe pustular psoriasis: 6 years later.
J Eur Acad Dermatol Venereol 22(10):1253-1254, 2008
313. Umezawa Y et al: Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res 295(Suppl. 1):S43-S54, 2003
314. Onoufriadis A et al. Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. Am J Hum Genet. 2011;doi:10.1016/j.ajhg.2011.07.022
315. Marrakchi S et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365(7):620-628, 2011
316. Abou-Samra T et al: Generalized pustular psoriasis complicated by acute respiratory distress syndrome. Br J Dermatol 150(2):353-356, 2004
317. Breier-Maly J et al: Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). Dermatology 198(1):61-64, 1999
318. Oumeish OY, Parish JL: Impetigo herpetiformis. Clin Dermatol 24(2):101-104, 2006
319. Bajaj AK et al: Impetigo herpetiformis. Dermatologica 155(5):292-295, 1977
320. Kroumpouzos G, Cohen LM: Dermatoses of pregnancy. J Am Acad Dermatol 45(1):1-19, quiz 19-22, 2001
321. Faergemann J: Treatment of sebopsoriasis with
itraconazole.
Mykosen 28(12):612-618, 1985
322. Happle R: Linear psoriasis and ILVEN: Is lumping or splitting appropriate? Dermatology 212(2):101-102, 2006
323. Del Rosso JQ et al: Dermatologic diseases of the nail unit. In: Nails: Therapy, Diagnosis, Surgery, edited by RK Scher, CR Daniel. Philadelphia, W.B. Saunders, 1997, pp. 172-182
324. Kouskoukis CE, Scher RK, Ackerman AB: The “oil drop” sign of psoriatic nails. A clinical finding specific for psoriasis. Am J Dermatopathol 5(3):259-262, 1983
325. Kvedar JC, Baden HP: Nail changes in cutaneous disease. Semin Dermatol 10(1):65-70, 1991
326. Daneshpazhooh M et al: Tongue lesions in psoriasis: A controlled study. BMC Dermatol 4(1):16, 2004
327. Lerner MR, Lerner AB: Psoriasis and protein intake. Arch Dermatol 90:217-225, 1964
328. Mallbris L et al: Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54(4):614-621, 2006
329. Wittenberg GP, Oursler JR, Peters MS: Secondary amyloidosis complicating psoriasis. J Am Acad Dermatol 32(3):465-468, 1995
330. Mallbris L et al: Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19(3):225-230, 2004
331. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 32(6):982-986, 1995
332. Cohen AD, Weitzman D, Dreiher J: Psoriasis and hypertension: A case-control study. Acta Derm Venereol 90(1):23-26, 2010
333. Gelfand JM et al: The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126(10):2194-2201, 2006
334. Fortune DG et al: Psychologic factors in psoriasis: Consequences, mechanisms, and interventions. Dermatol Clin 23(4):681-694, 2005
335. Ginsburg IH, Link BG: Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 20(1):53-63, 1989
336. Gupta MA, Gupta AK, Watteel GN: Early onset (<40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: A study of 137 patients. Acta Derm Venereol 76(6):464-466, 1996
337. Cooper-Patrick L, Crum RM, Ford DE: Identifying suicidal ideation in general medical patients. JAMA 272(22):1757-1762, 1994
338. Finlay AY et al: Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 123(6):751-756, 1990
339. Rapp SR et al: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3 Pt 1):401-407, 1999
340. Krueger G et al: The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137(3):280-284, 2001
341. Herron MD et al: Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141(12):1527-1534, 2005
342. Fortes C et al: Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141(12):1580-1584, 2005
343. Kramer U, Esser C: Cigarette smoking, metabolic gene polymorphism, and psoriasis. J Invest Dermatol 126(3):693-694, author reply 695, 2006
344. Whyte J, Baughman R, Hanover N: Acute guttate psoriasis and streptococcal infection. Arch Dermatol 89:350-356, 1964
345. Mallon E et al: HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 139(3):527-533, 1998
346. Duvic M et al: Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol 123(12):1622-1632, 1987
347. Kaplan MH et al: Antipsoriatic effects of
zidovudine in human immunodeficiency virus-associated psoriasis.
J Am Acad Dermatol 20(1):76-82, 1989
348. Obuch ML et al: Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol 27(5 Pt 1):667-673, 1992
349. Colebunders R et al: Psoriasis regression in terminal AIDS. Lancet 339(8801):1110, 1992
350. Vittorio Luigi De Socio G, Simonetti S, Stagni G: Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis 38(1):74-75, 2006
351. Cohen AD et al: Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 220(3):218-222, 2010
352. O'Brien M, Koo J: The mechanism of
lithium and beta-blocking agents in inducing and exacerbating psoriasis.
J Drugs Dermatol 5(5):426-432, 2006
353. Ko JM, Gottlieb AB, Kerbleski JF: Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat 16:1-8, 2008
354. van de Kerkhof PC: Therapeutic strategies: Rotational therapy and combinations. Clin Exp Dermatol 26(4):356-361, 2001
355. Lebwohl M, Ali S: Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 45(4):487-498, quiz 499-502, 2001
356. van de Kerkhof PC, Vissers WH: The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 16(2):69-83, 2003
357. Richards HL et al: Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 41(4):581-583, 1999
358. Griffiths CE et al: A systematic review of treatments for severe psoriasis. Health Technol Assess 4(40):1-125, 2000
359. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 60(4):643-659, 2009
360. Linden KG, Weinstein GD: Psoriasis: Current perspectives with an emphasis on treatment. Am J Med 107(6):595-605, 1999
361. du Vivier A, Phillips H, Hehir M: Applications of glucocorticosteroids. The effects of twice-daily vs once-every-other-day applications on mouse epidermal cell DNA synthesis. Arch Dermatol 118(5):305-308, 1982
362. Lehmann B: The vitamin D3 pathway in human skin and its role for regulation of biological processes. Photochem Photobiol 81(6):1246-1251, 2005
363. Barna M et al: Effect of
calcitriol on the production of T-cell-derived cytokines in psoriasis.
Br J Dermatol 136(4):536-541, 1997
364. Ramsay CA: Management of psoriasis with calcipotriol used as monotherapy. J Am Acad Dermatol 37(3 Pt 2):S53-S54, 1997
365. Mortensen L et al: Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. Acta Derm Venereol 73(4):300-304, 1993
366. Arbiser JL et al: Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol 126(6):1396-1402, 2006
367. Hecker D et al: Interactions between
tazarotene and ultraviolet light.
J Am Acad Dermatol 41(6):927-930, 1999
368. Zonneveld IM et al: Topical
tacrolimus is not effective in chronic plaque psoriasis. A pilot study.
Arch Dermatol 134(9):1101-1102, 1998
369. Gribetz C, Ling M, Lebwohl M et al:
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study.
J Am Acad Dermatol 51(5):731-738, 2004
370. Martin Ezquerra G et al: Topical
tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques.
J Drugs Dermatol 5(4):334-336, 2006
371. Lebwohl M: The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 38(1):16-24, 1999
372. Honigsmann H: Phototherapy for psoriasis. Clin Exp Dermatol 26(4):343-350, 2001
373. Ozawa M et al: 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 189(4):711-718, 1999
374. Walters IB et al: Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: Differential regulation of cytokines at the single-cell level. Arch Dermatol 139(2):155-161, 2003
375. van Weelden H et al: A new development in UVB phototherapy of psoriasis. Br J Dermatol 119(1):11-19, 1988
376. Green C et al: 311 nm UVB phototherapy–An effective treatment for psoriasis. Br J Dermatol 119(6):691-696, 1988
377. Van Weelden H et al: Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol 70(3):212-215, 1990
378. Tanew A et al: Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: A paired comparison study. Arch Dermatol 135(5):519-524, 1999
379. Yones SS et al: Randomized double-blind trial of the treatment of chronic plaque psoriasis: Efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 142(7):836-842, 2006
380. Iest J, Boer J: Combined treatment of psoriasis with
acitretin and UVB phototherapy compared with
acitretin alone and UVB alone.
Br J Dermatol 120(5):665-670, 1989
381. Green C et al: A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol 127(1):5-9, 1992
382. Passeron T, Ortonne JP: Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol 24(1):33-42, 2006
383. Speight EL, Farr PM: Erythemal and therapeutic response of psoriasis to PUVA using high-dose UVA. Br J Dermatol 131(5):667-672, 1994
384. Asawanonda P et al: 308-nm excimer laser for the treatment of psoriasis: A dose-response study. Arch Dermatol 136(5):619-624, 2000
385. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 62(1):114-135, 2010
386. Radakovic-Fijan S et al: Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol 152(2):279-283, 2005
387. Halevy S, Sukenik S: Different modalities of spa therapy for skin diseases at the Dead Sea area. Arch Dermatol 134(11):1416-1420, 1998
388. Lebwohl M, Ali S: Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 45(5):649-661, quiz 662-644, 2001
389. Strober BE, Siu K, Menon K: Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 33(7):1442-1446, 2006
390. Pathirana D et al: European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(Suppl. 2):1-70, 2009
391. Jeffes EW III et al:
Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of
methotrexate.
J Invest Dermatol 104(2):183-188, 1995
392. Cronstein BN, Naime D, Ostad E: The antiinflammatory effects of
methotrexate are mediated by
adenosine.
Adv Exp Med Biol 370:411-416, 1994
393. Strober BE, Menon K: Folate supplementation during
methotrexate therapy for patients with psoriasis.
J Am Acad Dermatol 53(4):652-659, 2005
394. Johnston A et al: The anti-inflammatory action of
methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules.
Clin Immunol 114(2):154-163, 2005
395. Kalb RE et al:
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.
J Am Acad Dermatol 60(5):824-837, 2009
396. Menon K et al: Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 62(2):291-299
397. Roenigk HH Jr et al:
Methotrexate in psoriasis: Revised guidelines.
J Am Acad Dermatol 19(1 Pt 1):145-156, 1988
398. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61(3):451-485, 2009
399. Orion E, Matz H, Wolf R: The life-threatening complications of dermatologic therapies. Clin Dermatol 23(2):182-192, 2005
400. Kazlow DW et al: Cutaneous ulceration caused by
methotrexate.
J Am Acad Dermatol 49(2 Suppl. Case Reports):S197-S198, 2003
401. Lee CS, Koo J: A review of
acitretin, a systemic retinoid for the treatment of psoriasis.
Expert Opin Pharmacother 6(10):1725-1734, 2005
402. Pilkington T, Brogden RN:
Acitretin. A review of its pharmacology and therapeutic use.
Drugs 43(4):597-627, 1992
403. Zachariae H et al: Morphologic renal changes during
cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens.
J Am Acad Dermatol 26(3 Pt 2):415-419, 1992
404. Nakayama J, Koga T, Furue M: Long-term efficacy and adverse event of
nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
Eur J Dermatol 8(8):563-568, 1998
405. Paul CF et al: Risk of malignancies in psoriasis patients treated with
cyclosporine: A 5 y cohort study.
J Invest Dermatol 120(2):211-216, 2003
406. Mrowietz U, Christophers E, Altmeyer P: Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 141(3):424-429, 1999
407. Gupta AK et al:
Sulfasalazine improves psoriasis. A double-blind analysis [see comments].
Arch Dermatol 126(4):487-493, 1990
408. Hollander JL et al: The effect of
triamcinolone on psoriatic arthritis-a two year study.
Arthritis Rheum 2:513-525, 1959
409. Zhou Y et al:
Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial.
J Cutan Med Surg 7(3):193-197, 2003
410. Mason C, Krueger GG:
Thioguanine for refractory psoriasis: a 4-year experience.
J Am Acad Dermatol 44(1):67-72, 2001
411. Kao NL, Rosenblate HJ: 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 28(6):1017-1018, 1993
412. Kirby B et al: Dermatomyositis-like eruption and leg ulceration caused by
hydroxyurea in a patient with psoriasis.
Clin Exp Dermatol 25(3):256-257, 2000
413. Weinblatt ME et al: A trial of
etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving
methotrexate.
N Engl J Med 340(4):253-259, 1999
414. Gottlieb AB, Bos JD: Recombinantly engineered human proteins: Transforming the treatment of psoriasis. Clin Immunol 105(2):105-116, 2002
415. van de Kerkhof PC: Consistent control of psoriasis by continuous long-term therapy: The promise of biological treatments. J Eur Acad Dermatol Venereol 20(6):639-650, 2006
416. Kazlow Stern D et al: The use of systemic immune moderators in dermatology: An update. Dermatol Clin 23(2):259-300, 2005
417. Sterry W et al: Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 151(Suppl. 69):3-17, 2004
418. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345(4):248-255, 2001
419. Werther WA et al: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157(11):4986-4995, 1996
420. Krueger J et al: Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 115(2):333, 2000
421. Leonardi CL: Efalizumab: An overview. J Am Acad Dermatol 49(2 Suppl.):S98-S104, 2003
422. Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35-47,2010
423. Feldmann M, Maini RN: Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9(10):1245-1250, 2003
424. Rigby WF: Distinct mechanisms of action of tumor necrosis factor antagonists: What are the clinical implications? Semin Arthritis Rheum 34(5 Suppl. 1):1-2, 2005
425. Scallon B et al: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301(2):418-426, 2002
426. Chien AL, Elder JT, Ellis CN:
Ustekinumab: A new option in psoriasis therapy.
Drugs 69(9):1141-1152, 2009
427. Kreymborg K et al: IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 179(12):8098-8104, 2007
428. Griffiths CE et al: Comparison of
ustekinumab and
etanercept for moderate-to-severe psoriasis.
N Engl J Med 362(2):118-128, 2010
429. Cather JC, Cather JC, Abramovits W: Investigational therapies for psoriasis. J Am Acad Dermatol 49(2 Suppl.):S133-S138, 2003
430. Russell CB et al: Blockade of the IL17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin [abstract]. J Invest Dermatol 130:S46, 2010
431. Chan CS et al: Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 60(6):962-971, 2009
432. Kalb RE et al: Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 60(1):120-124, 2009
433. Frankel AJ et al: Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 61(6):1044-1055, 2009
434. Rosenbach M et al: Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 62(4):655-662, 2010
435. Kastelan M et al: Perforin expression is upregulated in the epidermis of psoriatic lesions. Br J Dermatol 151(4):831-836, 2004
436. Iordanov MS et al: Cell death-induced activation of epidermal growth factor receptor in keratinocytes: Implications for restricting epidermal damage in dermatitis. J Invest Dermatol 125(1):134-142, 2005
437. Wolff K et al: Phototesting and dosimetry for photochemotherapy. Br J Dermatol 96(1):1-10, 1977
438. Gerber W et al: Ultraviolet B 308-nm excimer laser treatment of psoriasis: A new phototherapeutic approach. Br J Dermatol 149(6):1250-1258, 2003
439. Feldman SR et al: Efficacy of the 308-nm excimer l